Impact of individual-level characteristics and transmission mitigation behaviors on SARS-

CoV-2 infection and seroprevalence in a large Northern California Bay Area cohort

Authors: Cameron Adams, MPH[1], Mary Horton, MPH[1], Olivia Solomon, MPH, Marcus Wong,

Sean L. Wu, PhD, Sophia Fuller, MA, Xiaorong Shao, MA, Indro Fedrigo, Hong L. Quach,

Diana L. Quach, Michelle Meas, MPH, Luis Lopez, Abigail Broughton, Anna L. Barcellos,

MPH, Joan Shim, Yusef Seymens, Samantha Hernandez, Magelda Montoya, Darrell M. Johnson,

MS, Kenneth B. Beckman, PhD, Michael P. Busch, MD, Josefina Coloma, PhD, Joseph A.

Lewnard, PhD, Eva Harris, PhD[2], Lisa F. Barcellos, PhD[2]

Affiliations: University of California, Berkeley, California, USA (C. Adams, M. Horton, O.

Solomon, M. Wong, S. Fuller, X. Shao, I. Fedrigo, H.L. Quach, D.L. Quach, M. Meas, L. Lopez,

A. Broughton, A.L. Barcellos, J. Shim, Y. Seymens, S. Hernandez, M. Montoya, J. Coloma, J.A.

Lewnard, E. Harris, L.F. Barcellos); Institute for Health Metrics and Evaluation, University of

Washington, Seattle, Washington, USA (S.L. Wu); University of Minnesota Genomics Center,

Minneapolis, Minnesota, USA (D.M. Johnson, K.B. Beckman); Vitalant Research Institute, San

Francisco, California, USA (M.P. Busch)

Abstract

Comprehensive data on transmission mitigation behaviors and SARS-CoV-2 infection

and serostatus are needed from large, community-based cohorts to identify SARS-CoV-2 risk

factors and impact of public health measures. From July 2020 to March 2021, ≈5,500 adults from

the East Bay Area, California were followed over three data collection rounds. We estimated the

prevalence of antibodies from SARS-CoV-2 infection and COVID-19 vaccination, and self-

reported COVID-19 test positivity. Population-adjusted SARS-CoV-2 seroprevalence was low,

increasing from 1.03% (95% CI: 0.50-1.96) in Round 1 (July-September 2020), to 1.37% (95%

CI: 0.75-2.39) in Round 2 (October-December 2020), to 2.18% (95% CI: 1.48-3.17) in Round 3

(February-March 2021). Population-adjusted seroprevalence of COVID-19 vaccination was

21.64% (95% CI: 19.20-24.34) in Round 3. Despite >99% of participants reporting wearing

masks, non-Whites, lower-income, and lower-educated individuals had the highest SARS-CoV-2

seroprevalence and lowest vaccination seroprevalence. Our results demonstrate that more

effective policies are needed to address these disparities and inequities.

Introduction

The first confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

infection in the California Bay Area was reported on February 28, 2020.(1) In response,

measures to prevent transmission were implemented soon after and included shelter-in-place

orders, mask mandates, business and school closures, and social distancing recommendations.

Despite these measures, spikes in reported infections occurred from July to September 2020 and

December 2020 to February 2021.(2)

Local public health and healthcare systems experienced major challenges in preventing

infections, identifying COVID-19 cases, and ensuring adherence to transmission mitigation

strategies. Furthermore, disparities and inequities in COVID-19 have been observed in the

United States(3) and there are few studies investigating the association of risk behaviors with

infection outcomes at the individual level.(4–6) A detailed understanding of the effectiveness of

transmission mitigation behaviors and sociodemographic factors that contribute to the

dipropionate impact of COVID-19 in vulnerable communities is critical. Public health and policy

directives aimed at controlling ongoing transmission, developing future prevention strategies,

and targeting health disparities and inequities must evidence-based. Large population-

representative cohorts with individual-level data on social and behavioral factors[7] associated

with COVID-19 and SARS-COV-2 infection and serostatus[8–12] are needed.

To address this need, we investigated individual-level characteristics and mitigation

behaviors that contributed to SARS-CoV-2 seroprevalence, self-reported infection, and viral

infection, and other outcomes in a large, population-based sample of over 5,500 individuals from

12 East Bay cities in Northern California followed longitudinally. During three time periods

from July 2020 to April 2021, we estimated the population-adjusted prevalence of SARS-CoV-2

outcomes and differences by age, sex, race/ethnicity, ZIP code, and other demographic strata as

well as the effect of transmission mitigation behavior on SARS-CoV-2 prevalence.

Methods

Recruitment and participants

Recruitment and selection of study participants was completed using a screening phase

followed by a longitudinal study phase with three rounds of data collection (Figure 1). In the

screening phase, all residential addresses within the East Bay cities and communities of Albany,

Berkeley, El Cerrito, El Sobrante, Emeryville, Hercules, Kensington, Oakland, Piedmont, Pinole,

Richmond, and San Pablo (~307,000 residential households) were mailed an invitation to

complete a consent form and screening questionnaire. In a household, the individual aged 18

years or older with the next birthday was eligible to participate. Additional eligibility criteria

included living within the study region, willingness to provide biospecimens and questionnaire

responses, ability to read and speak English or Spanish, and having internet access and an email

address.

The target sample size was 5,500 participants. The distribution of racial and ethnic

identification in the screening questionnaire responses was more White and non-Hispanic than

the region population. To obtain a sample that resembled the racial and ethnic proportions in the

2018 American Community Survey (ACS) for the study region, we ranked assigned ranks for

order of inclusion to all eligible individuals who responded to the screening questionnaire. Black

and/or Hispanic individuals were ranked the highest followed by other non-Whites. Order of

inclusion for Whites was randomly sampled. In Round 1, individuals ranked between 1 and

5,500 were offered study enrollment. Those who declined to enroll were replaced with next

highest ranked individuals who had not been offered study entry. In subsequent rounds,

individuals who had participated in the previous round(s) were offered participation in the next

round. If participation was declined, individuals from the pool of participants who had not

participated in a study round were invited. Approximate dates for each round were July-

September 2020, October-December 2020, and February-March 2021.

All participants provided their informed consent for the screening phase. All participants

in the study phase provided their informed consent for each study round. The study was

approved by the University of California, Berkeley Committee on Protection of Human Subjects

(Protocol #2020-03-13121).

Study procedures

At the start of each round, eligible participants were invited to participate. Those who

agreed to participate received a kit via FedEx containing materials for self-collection of

biospecimens, pre-paid return shipping labels, and instructions to complete an online-

administered questionnaire at the same time as biospecimen collection.

Questionnaire

The questionnaire addressed sex, gender, age, race/ethnicity, income, employment, physical and mental health, as well as symptoms potentially related to COVID-19 within the previous 2 weeks, and SARS-CoV-2 testing outside of the study. Participants were also asked about behaviors that might affect risk of SARS-CoV-2 infection including physical distancing practices, close contacts with others, and mask wearing. Questionnaires were available in English or Spanish.

SARS-CoV-2 viral and antibody testing

Anterior nasal nare swabs for viral RNA testing and dried blood spots (DBS) for antibody testing were collected from participants at each study round. Quantitative reverse transcription PCR (RT-qPCR) was used to identify SARS-CoV-2 viral infection. Three tests were used to assess anti-SARS-CoV-2 antibodies in DBS: Ortho VITROS® Anti-SARS-CoV-2 Total IgG and spike IgG ELISA targeted antibodies against the SARS-CoV-2 spike protein (indicating prior natural infection or vaccination), and Roche-NC Total IgG targeted antibodies against the nucleocapsid (NC) protein (indicating prior natural infection only).(13) Before COVID-19 vaccines were available in the study region during rounds 1 and 2, detection of antibodies against the SARS-CoV-2 spike protein was considered evidence of SARS-CoV-2 infection. During Round 3, vaccinations were widely available, therefore detection of antibodies against the NC protein were considered evidence of SARS-CoV-2 infection, while detection of antibodies against the spike protein were considered evidence of SARS-CoV-2 infection or COVID-19 vaccination (Supplement S-4.2, Figure S-1).

SARS-CoV-2 outcomes

The following outcomes were investigated in each round: (1) cumulative SARS-CoV-2 antibody positivity, (2) participants' self-reported history of SARS-CoV-2 positivity from RT-

qPCR testing outside the study, (3) and a surveillance definition of "probable COVID-19 case"

derived from self-reported symptoms and close contact with infected individuals(14), and (4)

viral SARS-CoV-2 positivity from RT-qPCR testing of nasal swabs (Supplement 4.2). We also

investigated antibodies induced by COVID-19 vaccination only in Round 3. SARS-CoV-2

antibody positivity was defined as having detectable antibodies in the current and/or previous

round(s). DBS samples that tested both negative for anti-NC antibodies and positive for anti-

spike antibodies in Round 3 were considered to have antibodies from COVID-19 vaccination

alone. Self-reported COVID-19 viral positivity prevalence was defined as the proportion of

participants reporting a positive viral test among all participants who reported being tested within

a study round. Probable COVID-19 case prevalence was defined as the proportion of participants

identified as a probable COVID-19 case among all participants who provided valid responses

within a study round. Viral positivity prevalence was defined as testing positive by RT-qPCR

from nasal swab samples.

Statistical analysis

Population-adjusted seroprevalence and other SARS-CoV-2 outcomes

Bayesian multilevel regression and poststratification (MRP) was used to estimate

population-adjusted cumulative seroprevalence, self-reported SARS-CoV-2 viral positivity

prevalence at each study round, and "probable COVID-19" prevalence at each study round. MRP

is a regression-based method for estimating population and sub-population averages from survey

data that has been shown to perform better than survey weighting, particularly with sparse data

(15,16).

In addition to estimation of regional prevalence of our outcomes, we estimated

prevalence within demographic groups and geographic areas in the study region. Variables of

interest were gender, age, race, Hispanic ethnicity, income, education, household size, and ZIP

code. We used a method described by Leeman and colleagues to generate a synthetic population

for poststratification using data from the 2018 American Community Survey (ACS) and the

Public Use Microdata Sample (PUMS).(16) Poststratification was done using binary sex because

gender is not reported by the ACS. Race and ethnicity were combined into a single variable to

reduce the number of poststratification strata.

At each study round, binary SARS-CoV-2 outcomes were modeled as a function of

geographic and demographic characteristics using multilevel logistic regression models.

Participant sex was included as a fixed effect. Vectors of random intercepts were defined for

each category of race/ethnicity, age, education, income, household size, and ZIP code and two-

way interactions between ZIP code, race/ethnicity, educational attainment, income, and age. To

improve estimation of geographic effects we allowed for spatial correlations using the modified

Besag-York-Mollié model and included the proportion of Spanish speaking households within

the ZIP code of residence from the ACS as a fixed effect (Supplement S-6).(17)

SARS-CoV-2 outcome prevalence and measures of association

We report populated-adjusted prevalence of SARS-CoV-2 outcomes across the study

region and within geographic and demographic groups of interest. To calculate prevalence

estimates, posterior distributions of the relevant poststratification stratum were aggregated. We

also estimated prevalence differences (PD) and prevalence ratios (PR) for the association

between populated-adjusted SARS-CoV-2 outcomes and race/ethnicity, education, and sex. For

each parameter of interest, the mean of the posterior distribution was the point estimate, and the

95% credible interval (CI) was the 2.5% and 97.5% quantiles of a posterior distribution.

SARS-CoV-2 test-kit bias corrected seroprevalence

We estimated cumulative SARS-CoV-2 seroprevalence at each study round adjusted for

the net sensitivity and specificity of the SARS-CoV-2 antibody testing algorithm in each study

round (Supplement S-6).

Transmission mitigation behavior analyses

In each round, participants were asked about physical distancing practices, recent close

contacts with others, mask wearing, and other behaviors and activities that might affect the risk

of SARS-CoV-2 infection. We classified participants into two behavior categories, "high-risk"

and "low-risk", with those responses using latent class analysis.(18) Crude associations between

behavior categories and characteristics such as sex, age, race/ethnicity, education, and income

were assessed with χ^2 tests. Associations between high-risk vs. low-risk behavior and within

round SARS-CoV-2 seroprevalence and self-reported test positivity were estimated using the

MRP model described above with random intercepts for behavior categories and interactions

between the behavior categories and ZIP code, age, race/ethnicity, education, and income

(Supplement S-5 and S-6).

Statistical analyses were completed in R 4.0.2. NIMBLE was used to implement MRP

models.(19) Detailed descriptions of MRP methods and code are provided in Supplementary

Methods and at github.com/adams-cam/ebcovid_prev.

Results

Enrollment and characteristics of study participants

Of the 16,115 residents who consented and completed the screening procedures between May-

July 2020, 1,777 did not satisfy inclusion criteria and were excluded (Figure 1). Characteristics

of participants are presented in Table 1 and Table S-1. Participation rates were high (Round 1:

76.8%, Round 2: 89.8%, and Round 3: 87.3%), and participants identified predominantly as

female (~63%). Those aged 45-64 years were the largest age group of participants across all

study rounds (ranging from 37.3% to 39.4%). Most participants identified as White (52.5% to

63.3%), followed by Asian/Pacific Islander (13.9% to 15.7%), Hispanic (11.0% to 15.6%), two

or more races (6.9% to 9.1%), African American or Black (3.0% to 4.9%), and Native

American/Alaska Native or other (1.7% to 2.2%).

Of those who completed the questionnaire, 87.3%, 95.3%, and 96.6% provided DBS and

93.6%, 98.1% and 98.% provided nasal swabs in rounds 1, 2, and 3, respectively (Table 2).

Antibodies against the SARS-CoV-2 spike protein were detected in 29 (0.6%) and 33 (0.6%) of

DBS in rounds 1 and 2, respectively. In Round 3, NC antibodies from natural infection alone

were detected in 84 participants (1.8% of 4,806) and spike antibodies from natural infection or

vaccination were detected in 1,452 participants (31.3% of 4,806). Viral infection was detected in

less than three nasal swabs in each round. The proportion of participants reporting both receiving

a SARS-CoV-2 test outside the study and testing positive within a study round increased over the

study period; 10/1,030 (1.0%) participants reporting a positive COVID-19 result in Round 1,

19/2,059 (0.9%) in Round 2, and 53/1892 (2.8%) in Round 3. In all rounds, few participants met

the criteria for being a COVID-19 probable case (<0.5%) (Table S-2).

Population adjusted SARS-CoV-2 outcome prevalence in study region

Population adjusted SARS-CoV-2 seroprevalence, self-reported COVID-19 test

positivity, and probable COVID-19 cases are reported in Table 3. Overall, populated-adjusted

SARS-CoV-2 natural infection seroprevalence was low across the study region: Round 1 (July-

September 2020) 1.03% (95% CI 0.50-1.96), Round 2 (October-December 2020 1.37% (0.75-

2.39), and Round 3 (February-March 2021) 2.18% (95% CI 1.48-3.17). In Round 3 the

populated-adjusted seroprevalence of COVID-19 vaccination was 21.64% (95% CI: 19.2, 24.34).

Models incorporating sensitivity and specificity of the antibody assays yielded lower SARS-

CoV-2 seroprevalence estimates in Round 1, similar estimates in Rounds 2 and 3, and a higher

estimate of COVID-19 vaccine seroprevalence in Round 3. Population adjusted self-reported test

positivity to SARS-CoV-2 was similar in Rounds 1 (1.11%, 95 CI: 0.39-2.40) and 2 (1.29%,

95% CI: 0.55, 2.17) to seroprevalence estimates and increased to 4.58% (95% CI: 2.56-7.64) in

Round 3. Population-adjusted prevalence of being a COVID-19 probable case was <1% across

rounds (Figure S-2).

SARS-CoV-2 seroprevalence and infection vary by geographic area

There was evidence for spatial differences in both populated-adjusted seroprevalence and

self-reported test positivity (Figure 2). The northern areas (Richmond, San Pablo, Pinole, and

Hercules) and southern areas (East Oakland) of the study region had higher seroprevalence than

Berkeley, El Cerrito, and North/Downtown Oakland. Self-reported test positivity was also higher

in the northern and southern areas. These trends were consistent across study rounds.

Population adjusted seroprevalence and self-reported test positivity prevalence within subgroups

Differences in populated-adjusted seroprevalence were observed among demographic

groups (Figure 3). In Round 1, those aged less than 45 years had higher likelihood of antibody

positivity than those aged 45 or older, but this relationship reversed over time (Figure 3B). In

general, non-Whites consistently had a higher likelihood of antibody positivity than Whites

(Figure 3C). The likelihood of antibody positivity also differed by household income and

educational attainment, with those reporting a household income <$100,000 and less than a

college degree having a higher likelihood of antibody positivity than their comparison groups

(Figures 3D-E). Those in households with more than four people had a higher likelihood of

antibody positivity than those in households with four or less people (Figure 3F). There was no

clear relationship between sex and populated-adjusted seroprevalence (Figure 3A). Similar

relationships were seen between demographic groups and self-reported test prevalence (Figure S-

3).

COVID-19 vaccination seroprevalence differs by race/ethnicity and age

In Round 3, populated-adjusted COVID-19 vaccination seroprevalence was lower in all

non-White groups compared to Whites, (White vs. Non-White, PD: -4.35%, 95% CI: (-9.32, -

0.35), Figure 4, Table 4). The difference between racial/ethnic groups was largest among older

participants; non-Whites had a lower COVID-19 vaccination seroprevalence compared to Whites

among those aged between 65-74 (PD: -11.67%, 95% CI: (-20.98, -2.49)) and those aged 75 or

older (PD: -10.15%, 95% CI: (-22.25, 0.43)).

Mask-wearing and association between high-risk vs. low-risk behavior and seroprevalence

More than 99% of participants reported ever wearing a mask 99% reported wearing a

mask during leisure and exercise activities, >91% reported wearing a mask at work, and >88%

reported wearing a mask while shopping (Table S-3). After clustering participants into "low-

risk" and "high-risk" groups according to self-reported mitigation behaviors, most participants

were considered low-risk across the study rounds (70%, 82%, and 77%, respectively; Figure

5A). Behaviors with the largest differences in high- versus low-risk behavior were reporting

"yes" to: left the house for work, medical/healthcare, care of relative, or other, worked with

potential COVID-19 contact, attended a gathering, and traveled to county outside of residence

within last two weeks (Figure 5B). Age, race/ethnicity, and education were all associated

(p<0.001) with high- vs. low-risk groups (Table S-4), but we did not observe strong evidence for

an association between mitigation behavior and either seroprevalence or self-reported test

positivity (Table 5), although the point estimates indicate that "low-risk" behavior was

associated with lower seroprevalence.

Discussion

In the current study, we investigated individual-level characteristics and behaviors that

contributed to SARS-CoV-2 related outcomes, including seroprevalence and self-reported

infection, in a large, population-based sample of over 5,500 participants from 12 East Bay

(Northern California) cities. During three time periods from July 2020 to March 2021, we

estimated the population-adjusted prevalence of SARS-CoV-2 outcomes across the study region

and within strata of age, sex, race/ethnicity, ZIP code, and household size. We then characterized

behaviors to mitigate transmission of SARS-CoV-2 and their effects on related outcomes.

Overall, prevalence of SARS-CoV-2 outcomes for natural infection were low which may be

attributable to the high percentage of mask-wearing and other risk-mitigating behaviors among

our participants. COVID-19 vaccination seroprevalence estimates in Round 3 was greater than

20%, with non-Whites having much lower seroprevalence than Whites.

Despite the low overall SARS-CoV-2 seroprevalence and infection observed in our study,

ZIP code of residence, age, racial/ethnic identification, education, and income all contributed to

differences in seroprevalence. Specifically, non-Whites, those without a college degree, and

lower income households, had higher seroprevalence. Further, ZIP codes with higher proportions

of Spanish speakers had higher populated-adjusted seroprevalence estimates (Figure S-4). These

differences persisted despite the high rates of mask wearing reported by our study sample,

further adding to strong evidence that the risk of COVID-19 is distributed unequally and that

structural inequities play an important role in COVID-19 risk.(20–23) Moreover, during Round 3

(February-March 2021), COVID-19 vaccines were widely available across the study region. We

found that Whites had much higher prevalence of antibodies against the SARS-CoV-2 spike

protein in Round 3, indicative of vaccination status, than non-Whites, as reported

elsewhere.(3,24) Notably, this difference was largest among those aged 65 or older. These

findings demonstrate that in the first few months of vaccine availability in the Bay Area, large

disparities in vaccination rates by race/ethnicity were observed among older persons, and Whites,

the group with the lowest prevalence of SARS-CoV-2 infection, were more likely to be

vaccinated, further underscoring the inequities that exist surrounding the coronavirus pandemic.

280   Another key finding was that almost all participants reported wearing masks. This

contrasts with models of mask usage reported by the Institute for Health Metrics and Evaluation

which reported mask usage ranging between 75-82% from December 2020 through March 2021

in California.(25,26) Mask wearing is one the most effective behaviors for controlling

community spread of SARS-CoV-2 infection.(27) The high rate of mask usage by study

participants may partially explain why we did not detect a differences between high-risk and

low-risk mitigation behavior and SARS-CoV-2 prevalence, and partially explain why our

estimates of SARS-CoV-2 seroprevalence and self-report test positivity were lower than public

case reports. However, a recent study estimating SARS-CoV-2 seroprevalence from blood

donors reported seroprevalence in the Bay Area region of California that were similar to our

estimates through December 2020.(28)

291   A major strength of this study was the longitudinal design and collection of individual-

level data, including biospecimens for antibody and virus testing, which is challenging but much

needed in current studies of the pandemic. Comprehensive data on social distancing, self-

quarantine, mask wearing, working from home, and other public health and SARS-CoV-2

mitigation efforts are needed to inform current and future strategies of prevention and for whom

to target prevention efforts. At-home collection of biospecimens, including dried blood spots for

antibody testing, made it possible to regularly test participants without any in-person interaction.

This was a critical feature, particularly early in the pandemic, when recommendations were to

travel only for essential purposes and to limit in-person interactions. At-home sample collection

was used to obtain more than 30,000 biospecimens and is a feasible approach for even larger

populations and geographic regions.

One limitation of this study was the under-representation of certain demographics in our

sample. Supplementary mailings of recruitment postcards in Spanish were sent to residences in

ZIP codes with high proportions of Spanish speaking households. We also placed recruitment

flyers in local grocery stores and conducted outreach to community organizations, local

government officials, and school districts in the study region. Despite these efforts, non-Whites,

males, lower income households, and individuals with lower education and from lower

socioeconomic ZIP codes were underrepresented in our sample. Unhoused individuals were also

not captured in our sample. This was important given evidence that individuals who identify as

Hispanic or Black, and other underrepresented groups, are at the highest risk for COVID-19.(23)

These discrepancies may have led to underestimation of overall SARS-CoV-2 seroprevalence

and self-reported infection, although the MRP models may have somewhat minimized this effect

by pooling information across similar observed characteristics in the sample data. Our

seroprevalence estimates were consistent with weekly case prevalence reported by public health

agencies in ZIP codes with high response rates (Figure S-5).(29) Additionally, there may be

unmeasured confounding from variables not included in the analyses and self-selection bias from

some participants in COVID-19 research who may be more fervent adherers to COVID-19

public health measures. Finally, some individuals do not seroconvert after infection or

vaccination.

Our results underscore the substantial and persistent inequities that exist surrounding the

coronavirus pandemic. Non-Whites, lower-income, and lower-educated individuals had the

highest SARS-CoV-2 seroprevalence. This disparity in seroprevalence was observed despite near

universal rates of mask wearing in our sample. We also observed large differences in COVID-19

vaccination seroprevalence between racial and ethnic groups. More work must be done to

address these disparities and inequities, such as allocation of resources for high-risk communities

and strategies to mitigate the structural barriers posed by social and structural determinants of

health.

Acknowledgments

We want to acknowledge the contributions of the following individuals to this study: Ella

Parsons, Jordan Keen, Janine Solomon, Jose Salinas, Kevin Duong, Joseph Egbunikeokye, Maya

Talavera, Riya Shrestha, Colin Warnes, José Victor Zambrana, Nicholas Lo, Parnal Narvekar,

Fausto Bustos, Gregorio Dias, Reinaldo Mercado-Hernandez, Julia Huffaker, Raymond Montes,

Alexandra Zermeno, Alejandra Zeiger, William Dow, Michael Lu, Lila Krop, Kelly Lam, Yan

Zhang, Sarah Folkmanis, Sophie Zhai, Dingjun Chen, Ruben Vargas Ethan Garcia, Oliver Li,

Manisha Sahoo, Raina Walencewicz, Sophia Wang, Antonia Gibbs, Amrita Ramanathan,

Catherine Livelo, Taylor Worley, Amanda Tanaka, Savinnie Ho, Jane Liu Ryan Allen, Sofia

Soltero, Victoria Van Metter, Madeleine Fraix, Allie Coyne, Subeksha Sharma Lydia Yu,

Shreeya Garg, Sanjeet Paluru, Malika Saxena, Talia Panadero, Ayra Rahman, Joshua Calangian,

Dharaa Upadhyaya, Sophia Kemp, Ruhi Parikh, Amy Rich, Sophie Manoukian, Nola Vu, Crystal

Nguyen, Jordyn Pinochi, Alma Kuc, Siri Ylenduri, Manvir Kaur, Angikaar Chana, and Sannidhi

Sarvadhavabhatla, Benjamin T. Auch, Dinesha Walek, Evan Forsberg, Jerry Daniel, Veronica

Tonnell, Ji Hyun (Jay) Kim, Mary Nieuwenhuis. Creative Testing Solutions: Valerie Green,

Sherri Cyrus, Phillip Willamson, Brett Hirsch, Paul Contestable, Mars Stone, Joe Derisi, Emily

Crawford, Emily Ahlvin, Armando Diaz, and Favianna Rodriquez.

References

1. Eby K. Coronavirus Timeline: Tracking major moments of COVID-19 pandemic in San
   Francisco Bay Area [Internet]. ABC7 San Francisco. 2020 [cited 2021 Nov 29]. Available
   from: https://abc7news.com/6047519/

2. United States. Agency for Toxic Substances and Disease Registry. Geospatial Research A and
   SP, editor. CDC COVID data tracker. 2020 Sep 15; Available from:
   https://stacks.cdc.gov/view/cdc/96118

3. Njoku A, Joseph M, Felix R. Changing the Narrative: Structural Barriers and Racial and
   Ethnic Inequities in COVID-19 Vaccination. International Journal of Environmental
   Research and Public Health. 2021 Jan;18(18):9904.

4. Qualls N. Community Mitigation Guidelines to Prevent Pandemic Influenza — United States,
   2017. MMWR Recomm Rep [Internet]. 2017 [cited 2021 Nov 10];66. Available from:
   https://www.facebook.com/CDCMMWR

5. CDC. Interim pre-pandemic planning guidance : community strategy for pandemic influenza
   mitigation in the United States : early, targeted, layered use of nonpharmaceutical
   interventions [Internet]. [cited 2021 Nov 10]. Available from:
   https://stacks.cdc.gov/view/cdc/11425

6. Bell DM, World Health Organization Working Group on International and Community

Transmission of SARS. Public health interventions and SARS spread, 2003. Emerg Infect

Dis. 2004 Nov;10(11):1900–6.

7. Hutchins HJ. COVID-19 Mitigation Behaviors by Age Group — United States, April–June

2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [cited 2021 Nov 10];69. Available

from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6943e4.htm

8. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of

Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.

JAMA Internal Medicine. 2020 Dec 1;180(12):1576–86.

9. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19

Antibody Seroprevalence in Santa Clara County, California. medRxiv. 2020

Apr;2020.04.14.20062463-2020.04.14.20062463.

10. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of

SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on

April 10-11, 2020. JAMA. 2020 Jun 16;323(23):2425–7.

11. Self WH. Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a

Multistate Hospital Network — 13 Academic Medical Centers, April–June 2020. MMWR

Morb Mortal Wkly Rep [Internet]. 2020 [cited 2021 Nov 10];69. Available from:

https://www.cdc.gov/mmwr/volumes/69/wr/mm6935e2.htm

12. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al.

Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann

Epidemiol. 2020 Aug;48:23-29.e4.

13. Wong MP, Meas MA, Adams C, Hernandez S, Green V, Montoya M, et al. Development

and Implementation of Dried Blood Spot-based COVID-19 Serological Assays for

Epidemiologic Studies. medRxiv. 2021 Jan 1;2021.11.25.21266786.

14. CSTE Interim Position Statement: Update to COVID-19 Case Definition - Council of State

and Territorial Epidemiologists [Internet]. [cited 2021 Oct 13]. Available from:

https://www.cste.org/news/520707/CSTE-Interim-Position-Statement-Update-to-COVID-

19-Case-Definition.htm

15. Gelman A, Little TC. Poststratification Into Many Categories Using Hierarchical Logistic

Regression. Survey Research. 1997 Dec;23:127–35.

16. Leemann L, Wasserfallen F. Extending the Use and Prediction Precision of Subnational

Public Opinion Estimation: EXTENDING USE AND PRECISION OF MrP. American

Journal of Political Science. 2017 Oct;61(4):1003–22.

17. Simpson D, Rue H, Riebler A, Martins TG, Sørbye SH. Penalising Model Component

Complexity: A Principled, Practical Approach to Constructing Priors. Statist Sci [Internet].

2017 Feb 1 [cited 2021 Sep 15];32(1). Available from:

https://projecteuclid.org/journals/statistical-science/volume-32/issue-1/Penalising-Model-

Component-Complexity--A-Principled-Practical-Approach-to/10.1214/16-STS576.full

18. Linzer DA, Lewis JB. poLCA: An R Package for Polytomous Variable Latent Class

Analysis. Journal of Statistical Software. 2011 Jun 14;42:1–29.

19. de Valpine P, Turek D, Paciorek CJ, Anderson-Bergman C, Lang DT, Bodik R.

Programming with models: writing statistical algorithms for general model structures with

NIMBLE. Journal of Computational and Graphical Statistics. 2017 Apr 3;26(2):403–13.

20. Reitsma MB, Claypool AL, Vargo J, Shete PB, McCorvie R, Wheeler WH, et al.

Racial/Ethnic Disparities In COVID-19 Exposure Risk, Testing, And Cases At The

Subcounty Level In California. Health Affairs. 2021 Jun 1;40(6):870–8.

21. Paremoer L, Nandi S, Serag H, Baum F. Covid-19 pandemic and the social determinants of

health. BMJ. 2021 Jan 29;372:n129.

22. Abrams EM, Szefler SJ. COVID-19 and the impact of social determinants of health. Lancet

Respir Med. 2020 Jul;8(7):659–61.

23. Magesh S, John D, Li WT, Li Y, Mattingly-app A, Jain S, et al. Disparities in COVID-19

Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and Meta-

analysis. JAMA Network Open. 2021 Nov 11;4(11):e2134147.

24. Agarwal R, Dugas M, Ramaprasad J, Luo J, Li G, Gao G (Gordon). Socioeconomic privilege

and political ideology are associated with racial disparity in COVID-19 vaccination. PNAS

[Internet]. 2021 Aug 17 [cited 2021 Nov 10];118(33). Available from:

https://www.pnas.org/content/118/33/e2107873118

25. Reiner RC, Barber RM, Collins JK, Zheng P, Adolph C, Albright J, et al. Modeling COVID-

19 scenarios for the United States. Nat Med. 2021 Jan;27(1):94–105.

26. IHME | COVID-19 Projections [Internet]. Institute for Health Metrics and Evaluation. [cited

2021 Oct 1]. Available from: https://covid19.healthdata.org/

27. Brooks JT, Butler JC. Effectiveness of Mask Wearing to Control Community Spread of

SARS-CoV-2. JAMA. 2021 Mar 9;325(10):998–9.

28. Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, et al. Estimated US Infection-

and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-

May 2021. JAMA [Internet]. 2021 Sep 2 [cited 2021 Sep 30]; Available from:

https://doi.org/10.1001/jama.2021.15161

29. The Los Angeles Times' open-source archive of California coronavirus data [Internet]. Los

Angeles Times Data and Graphics Department; 2021 [cited 2021 Oct 12]. Available from:

https://github.com/datadesk/california-coronavirus-data

Address for correspondence: Lisa F. Barcellos, 324 Stanley Hall, Berkeley, CA 94720,

lbarcellos@berkeley.edu, 510-642-7814

Table 1. Characteristics of participants at each round of the study compared to study region

population.

	PS Strata† %	Round 1 no. (%)	Round 2 no. (%)	Round 3 no. (%)
Invited to round		7166	6242	5506
Participated in study round		5501 (76.8)	5603 (89.8)	4806 (87.3)
Gender				
Female		3451 (62.7)	3509 (62.6)	3040 (63.3)
Male		1996 (36.3)	2036 (36.3)	1721 (35.8)
Other		51 (0.9)	52 (0.9)	40 (0.8)
Missing		3 (0.1)	6 (0.1)	5 (0.1)
Sex				
Female	51.8	3502 (63.7)	3559 (63.5)	3080 (64.1)
Male	48.2	1996 (36.3)	2042 (36.4)	1725 (35.9)
Missing		3 (0.1)	2 (0)	1 (0)
Age				
18-29	24.2	476 (8.7)	378 (6.7)	286 (6)
30-44	29.0	1768 (32.1)	1656 (29.6)	1330 (27.7)
45-64	30.0	2052 (37.3)	2141 (38.2)	1895 (39.4)
65-74	10.2	928 (16.9)	1077 (19.2)	977 (20.3)
75+	6.6	275 (5)	345 (6.2)	313 (6.5)
Missing		2 (0)	6 (0.1)	5 (0.1)
Race/ethnicity				
African American/Black	17.4	268 (4.9)	180 (3.2)	146 (3)
American Indian/Alaska Native/Other	0.5	123 (2.2)	114 (2)	84 (1.7)
Asian/Pacific Islander	20.3	862 (15.7)	763 (13.6)	668 (13.9)
Hispanic	22.4	860 (15.6)	637 (11.4)	527 (11)
Two or more races	3.8	500 (9.1)	400 (7.1)	334 (6.9)
White	35.6	2886 (52.5)	3503 (62.5)	3041 (63.3)
Missing		2 (0)	6 (0.1)	6 (0.1)
Educational attainment				
College degree or more	47.0	4912 (89.3)	5101 (91)	4404 (91.6)
Less than college degree	53.0	552 (10)	496 (8.9)	399 (8.3)
Missing		37 (0.7)	6 (0.1)	3 (0.1)
Current annual household income, USD				
<$100K	62.9	2081 (37.8)	2075 (37)	1779 (37)
≥$100K	37.1	3192 (58)	3347 (59.7)	2866 (59.6)
Missing		228 (4.1)	181 (3.2)	161 (3.3)

*PS, Poststratification; USD, United States Dollar.
†Population percentages from synthetic poststratification tables generated from American Community Survey (ACS) and Public Use Microdata Sample data. Each cell contains the percentage of population age >18. Gender is not available in ACS data.

442 Table 2. Prevalence of SARS-CoV-2 related outcomes among participants per study round.

	Round 1	Round 2	Round 3
Biospecimen collection period	Jul. 4, 2020 – Sep. 1, 2020	Oct. 10, 2020 – Dec. 16, 2020	Feb. 11, 2021 – Mar. 20, 2021
N	5501	5603	4806
Provided DBS, no. (%)	4801 (87.3)	5340 (95.3)	4641 (96.6)
Provided nasal swab, no. (%)	5148 (93.6)	5499 (98.1)	4735 (98.5)
SARS-CoV-2 spike antibody status†, no. (%)			
Non-reactive	4641 (96.7)	5275 (98.8)	3157 (68.0)
QNS	131 (2.7)	31 (0.6)	32 (0.7)
Reactive	29 (0.6)	33 (0.6)	1452 (31.3)
SARS-CoV-2 nucleocapsid antibody status‡, no. (%)			
Non-reactive			4181 (90.1)
QNS			376 (8.1)
Reactive			84 (1.8)
SARS-CoV-2 viral status, no. (%)			
Invalid/Inconclusive	4 (0.1)	5 (0.1)	7 (0.1)
Not Detected	5143 (99.9)	5491 (99.9)	4725 (99.8)
Positive 2019-nCoV	1 (0.0)	3 (0.1)	3 (0.1)
Self-reported positive COVID-19 test, no. (%)			
No	1020 (18.5)	2059 (36.7)	1892 (39.4)
Yes	10 (0.2)	19 (0.3)	53 (1.1)
Not tested	4471 (81.3)	3525 (62.9)	2861 (59.5)
Probable COVID-19 case§, no. (%)			
No	4800 (87.3)	4938 (88.1)	4419 (91.9)
Yes	21 (0.4)	10 (0.2)	8 (0.2)
Not reported	680 (12.4)	655 (11.7)	379 (7.9)

*DBS, dried blood spot; QNS, quantity not sufficient.
†Antibody assays specific to spike antibodies detect presence of antibodies induced by SARS-CoV-2 natural infection or vaccination.
‡Antibody assays specific to nucleocapsid antibodies detect presence of antibodies induced by SARS-CoV-2 natural infection.
§As defined by the Council for State and Territorial Epidemiologists.

459   Table 3. Estimated population-adjusted prevalence (%) and 95% credible intervals within study

460   region of SARS-CoV-2 outcomes.

SARS-CoV-2 Outcome	Round 1 Prev.% (95% CI)	Round 2 Prev. % (95% CI)	Round 3 Prev. % (95% CI)
SARS-CoV2 Ab+ NI†			
Crude	29/4670 = 0.62%	48/5949 = 0.81%	110/5991 = 1.83%
Pop-adjusted‡	1.03 (0.50, 1.96)	1.37 (0.75, 2.39)	2.18 (1.48, 3.17)
Pop-adjusted + Test-bias adjusted§	0.63 (0.04, 2.00)	1.02 (0.17, 2.40)	2.19 (1.49, 3.18)
SARS-CoV2 Ab+ V¶			
Crude			1369/4608 = 29.7%
Pop-adjusted‡			21.64 (19.2, 24.34)
Pop-adjusted + Test-bias adjusted§			27.56 (22.84, 33.55)
Self-reported test positivity#			
Crude	10/1030 = 0.97%	19/2078 = 0.91%	53/1945 = 2.73%
Pop-adjusted‡	1.11 (0.39, 2.40)	1.29 (0.55, 2.71)	4.58 (2.56, 7.64)
Probable COVID-19 case¶			
Crude	21/4821 = 0.44%	10/4948 = 0.2%	8/4427 = 0.18%
Pop-adjusted‡	0.59 (0.26, 1.19)	0.64 (0.17, 1.75)	0.65 (0.17, 1.77)

*Ab, antibody; NI, natural infection; Prev., prevalence; V, vaccination.
†Estimate of cumulative antibody prevalence from natural infection by SARS-CoV-2.
‡Population-adjusted prevalence estimated using multilevel regression and poststratification models.
§Population-adjusted prevalence estimated using multilevel regression and poststratification models that included expressions for antibody assay sensitivity and specificity.
¶Estimate of cumulative prevalence of antibodies from natural infection by SARS-CoV-2 or COVID-19 vaccination.
#Estimated within round prevalence of self-reported COVID-19 test positivity.
††Estimated within round prevalence of COVID-19 probable case.

463 Table 4. Round 3 seroprevalence of antibodies from COVID-19 vaccination within race/ethnicity

464 and age groups and prevalence differences between non-Whites and Whites.

	Within group Prev. % (95% CI)†	Non-whites compared to whites PD % (95% CI)‡
Race/ethnicity		
White	25.33 (23.14, 27.65)	Ref
African American/Black	19.69 (13.47, 26.13)	-5.65 (-12.17, 0.76)
American Indian/Alaska Native/Other	18.87 (12.32, 25.95)	-6.46 (-13.3, 0.51)
Asian/Pacific Islander	21.34 (17.24, 26.13)	-4 (-8.4, 0.93)
Hispanic	18.64 (13.74, 24.4)	-6.69 (-11.83, -0.81)
Two or more races	15.74 (11.85, 19.94)	-9.6 (-13.88, -5.28)
All non-white	19.6 (16.16, 23.33)	-4.35 (-8.32, -0.35)
Age group, y		
18-29	15.04 (10.92, 19.81)	-3.2 (-9.14, 2.23)
30-44	16.53 (13.84, 19.57)	-1.94 (-6, 2.74)
45-64	16.6 (13.99, 19.61)	-1.04 (-5.44, 3.89)
65-74	45.74 (40.72, 50.75)	-11.67 (-20.98, -2.49)
75 +	54.01 (46.12, 61.79)	-10.15 (-22.25, 0.43)

*CI, credible interval; PD, prevalence difference; Prev, prevalence.

†Population adjusted seroprevalence in round 3 estimated using multilevel regression and poststratification (MRP); Seroprevalence and 95% CI are the mean and 2.5% and 97.5% quantiles of a posterior distribution respectively. Assay used detects antibodies from natural SARS-CoV-2 infection or from COVID-19 vaccination.

‡Population adjusted COVID-19 seroprevalence difference in round 3 between each race/ethnicity group and Whites among race/ethnicity and between non-Whites and Whites within each age group. PDs estimated using MRP, and the PDs and 95% CIs are the mean and 2.5% and 97.5% quantiles of a posterior distribution, respectively. A

467   Table 5. Association between seroprevalence and self-reported test positivity and high-risk vs.

468   low-risk mitigation behavior within each study round.

	MOA†	Round 1	Round 2	Round 3
SARS-CoV-2 antibody prevalence‡	PD % (95% CI)	-0.21 (-1.4, 0.79)	0.02 (-1.59, 1.03)	-0.46 (-2.23, 1.00)
	PR (95% CI)	0.93 (0.34, 2.03)	1.4 (0.32, 3.93)	0.88 (0.45, 1.57)
Self-reported test positivity	PD % (95% CI)	0.53 (-0.73, 2.24)	0.11 (-2.12, 1.6)	-1.11 (-5.26, 2.18)
	PR (95% CI)	2.17 (0.54, 6.72)	1.56 (0.33, 4.65)	0.87 (0.41, 1.64)

*CI, credible interval; MOA, measure of association; PD, prevalence difference; PR, prevalence ratio
†Populated adjusted prevalence estimated using multilevel regression and poststratification models; point estimate is the mean of a posterior distribution of the parameter, 95% credible interval estimated from 2.5% and 97.5% quantiles of a posterior distribution.
‡Defined as having detectable SARS-CoV-2 antibodies within a study round.

472   Figure 1. Study flow chart.

Figure 2. Population adjusted, A) cumulative seroprevalence of SARS-CoV-2 antibodies to

natural infection, and B) self-reported test positivity prevalence for (July 2020-April 2021)

across the study region.

480   Figure 3. Cumulative seroprevalence of SARS-CoV-2 anti-S antibodies (Rounds 1 and 2) and

481   anti-NC antibodies (Round 3) (July 2020-April 2021) among demographic subgroups, A) sex, B)

482   age, C) race/ethnicity, D) income, E) education, and F) household size. Abbreviations: AA,

483   African American; AMI, American Indian; PI, Pacific Islander.

Figure 4. Round 3 population-adjusted nucleocapsid (natural infection) seroprevalence compared

to spike (natural infection or vaccination) seroprevalence within strata of race/ethnicity and age.

Each point represents a stratum of race/ethnicity and age within a ZIP code, the size of the point

is proportional to American Community Survey population size.

A.

B.

Figure 5. Proportion of participants stratified by high- and low-risk mitigation behaviors in each

study round, A) overall, and B) according to specific behavior.

495